Advertisement

Topics

FDA approves biosimilar of Avastin to treat five types of cancer

01:59 EDT 15 Sep 2017 | Pharmaceutical Business Review

Amgen and Allergan have secured approval from the US Food and Drug Administration (FDA) for Mvasi (bevacizumab-awwb), a biosimilar to Roche's Avastin, to treat five types of cancer.

Original Article: FDA approves biosimilar of Avastin to treat five types of cancer

NEXT ARTICLE

More From BioPortfolio on "FDA approves biosimilar of Avastin to treat five types of cancer"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...